Key result
Alpha-1-adrenoreceptor blockade with prazosin reversed hypoxia-induced reductions in flow-mediated dilation, resulting in a 1.8% higher FMD compared to placebo at 330 minutes (P≤0.03).
Why the study?
Does alpha-1 adrenergic blockade with prazosin improve flow-mediated dilation during acute normobaric hypoxia in healthy participants?
RCT (n=11)
Does alpha-1 adrenergic blockade with prazosin improve flow-mediated dilation during acute normobaric hypoxia in healthy participants?
Mean Difference: 1.8
p-value: p=≤0.03
Acute hypoxia-induced reductions in flow-mediated dilation are largely mediated by the alpha-1 adrenoceptor pathway and can be partially reversed by prazosin.
Prazosin partially restores FMD in acute hypoxia; confirms alpha-1 mediation and supports targeted trials in at-risk populations.
Endothelium‐dependent flow‐mediated dilation (FMD) is impaired during exposure to high altitude. Although the time course and mechanism(s) governing this impairment are undefined, hypoxic‐induced elevations in sympathetic outflow may attenuate FMD. We examined the hypothesis that acute exposure to normobaric hypoxia would lead to reductions in FMD that could be reversed via adrenergic blockade. In a placebo‐controlled crossover experiment, brachial FMD, arterial oxygen saturation, blood pressure and heart rate (HR) were assessed in 11 healthy participants (aged 32±7 y) in normobaric normoxia and following 60 min, 210 min and 330 min of normobaric hypoxia (FIO 2 =0.11). At 210 min, participants ingested an α 1 ‐adrenoreceptor blocker (Prazosin; 1 mg/20 kg body mass) or an identical placebo. Compared to normoxic baseline, FMD was reduced following 60 min, 210, and 330 min of hypoxia by 1.6 ± 0.2% (relative change 28%), 2.5 ± 0.1% and 2.8 ± 0.2% (36%), respectively (P蠄0.003). Following α 1 ‐blockade, FMD and HR at 330 min were 5 ± 2 beats∙min ‐1 and 1.8 ± 1.4% (35%) higher compared with the placebo trial (P蠄0.03). In summary, sustained reductions in FMD occur within 60 min of exposure to normobaric hypoxia and are largely mediated via the α 1 ‐adrenoceptor pathway.
No takes yet. Share an insight, caveat, or question.
Lewis et al. (2014) conducted an RCT in Healthy (n=11). Prazosin (α1-adrenoreceptor blocker) vs. Placebo was evaluated on Flow-mediated dilation (FMD) at 330 min (MD 1.8%, p=≤0.03). Alpha-1-adrenoreceptor blockade with prazosin reversed hypoxia-induced reductions in flow-mediated dilation, resulting in a 1.8% higher FMD compared to placebo at 330 minutes (P≤0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: